Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China

被引:4
|
作者
Dun, Changchang [1 ,2 ]
Yuan, Meiwen [2 ]
Zhao, Xuelian [2 ]
Hu, Shangying [2 ]
Arbyn, Marc [3 ]
Zhao, Fanghui [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Dept Populat Med, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Epidemiol,Canc Hosp, Beijing, Peoples R China
[3] Sci Inst Publ Hlth, Belgian Canc Ctr, Unit Canc Epidemiol, Brussels, Belgium
来源
CANCER MEDICINE | 2024年 / 13卷 / 11期
关键词
cervical cancer; HPV genotyping; pooled analysis; screening; triage; INTRAEPITHELIAL NEOPLASIA; RISK; WOMEN; PREVALENCE; INFECTION; METAANALYSIS; PERFORMANCE;
D O I
10.1002/cam4.7316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To assess the clinical values of extended human papillomavirus (HPV) genotyping in triage of high-risk HPV-positive women, focusing on the trade-off between cervical precancer detections and colposcopy referrals. Methods: A bivariate random-effects model was used to estimate the diagnostic accuracy of primary HPV screening with following triage strategies to detect cervical precancers: (i) partial genotyping for HPV16/18 combined with cytological testing at atypical squamous cells of undetermined significance threshold (used as the comparator), (ii) genotyping for HPV16/18/58/52, (iii) genotyping for HPV16/18/58/52/33, (iv) genotyping for HPV16/18/58/33/31, (v) genotyping for HPV16/18/58/52/33/31, and (vi) genotyping for HPV16/18/58/52/33/31/39/51. Internal risk benchmarks for clinical management were used to evaluate the risk stratification of each triage strategy. Results: A total of 16,982 women (mean age 46.1 years, range 17-69) were included in this analysis. For CIN3+ detection, triage with HPV16/18/58/33/31 genotyping achieved lower positivity (6.85% vs. 7.35%, p = 0.001), while maintaining similar sensitivity (91.35% vs. 96.42%, p = 0.32) and specificity (94.09% vs. 93.67%, p = 0.56) compared with the comparator strategy. Similar patterns were observed for CIN2+ detection. Women with a positive HPV16/18/58/33/31 genotyping test had high enough risk for CIN3+ for colposcopy referral, while the risk for women with a negative test was below the 1-year return decision threshold according to internal benchmarks. Conclusions: Our findings suggested extended HPV genotyping is of potential to be used as a triage technique integrated into HPV-based cervical cancer screening, leading to reduced need for colposcopy referral while maintaining similar disease detection and efficient risk stratification.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Cervical cancer screening program integrating Pap smear and HPV DNA testing: A population-based study
    Chao, Angel
    Hsu, Kuang-Hung
    Lai, Chyong-Huey
    Huang, Huei-Jean
    Hsueh, Swei
    Lin, Sheue-Rong
    Jung, Shih-Ming
    Chao, Fang-Yu
    Huang, Shang-Lang
    Huang, Chu-Chun
    Yang, Jung-Erh
    Chang, Ting-Chang
    INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (12) : 2835 - 2841
  • [32] Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test
    Wright, Thomas C.
    Stoler, Mark H.
    Behrens, Catherine M.
    Sharma, Abha
    Zhang, Guili
    Wright, Teresa L.
    GYNECOLOGIC ONCOLOGY, 2015, 136 (02) : 189 - 197
  • [33] Clinical evaluation of p16INK4a immunocytology in cervical cancer screening: A population-based cross-sectional study from rural China
    Rezhake, Remila
    Wang, Yan
    Chen, Feng
    Hu, Shang-Ying
    Zhang, Xun
    Cao, Jian
    Qiao, You-Lin
    Zhao, Fang-Hui
    Arbyn, Marc
    CANCER CYTOPATHOLOGY, 2021, 129 (09) : 679 - 692
  • [34] Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option.: Experience from the LAMS Study
    Longatto-Filho, A.
    Roteli-Martins, C.
    Hammes, L.
    Etlinger, D.
    Pereira, S. M. Miranda
    Erzen, M.
    Branca, M.
    Naud, P.
    Derchain, S. F. M.
    Sarian, L. O.
    Matos, J.
    Gontijo, R.
    Lima, T.
    Maeda, M. Y. S.
    Tatti, S.
    Syrjanen, S.
    Syrjanen, K.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2008, 29 (04) : 327 - 332
  • [35] Comparison of Different HPV-based Strategies and Cytology in Routine Cervical Cancer Screening Programme in China: A Population-based Study
    Wang, Shi
    Li, Ling
    Yang, Jie
    Han, Na
    Bao, Heling
    Wang, Hai-Jun
    CANCER PREVENTION RESEARCH, 2022, 15 (01) : 45 - 54
  • [36] Recommendations for Implementing Human Papillomavirus-Based Cervical Cancer Screening: Lessons Learned from the HPV FOCAL Trial
    Smith, Laurie
    van Niekerk, Dirk
    Coldman, Andrew
    Krajden, Mel
    Franco, Eduardo L.
    Ogilvie, Gina
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2016, 38 (08) : 723 - 726
  • [37] Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study
    Lindquist, Sofie
    Kjaer, Susanne K.
    Frederiksen, Kirsten
    Ornskov, Dorthe
    Munk, Christian
    Waldstrom, Marianne
    GYNECOLOGIC ONCOLOGY, 2024, 191 : 45 - 55
  • [38] The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis
    Felix, Juan C.
    Lacey, Michael J.
    Miller, Jeffrey D.
    Lenhart, Gregory M.
    Spitzer, Mark
    Kulkarni, Rucha
    JOURNAL OF WOMENS HEALTH, 2016, 25 (06) : 606 - 616
  • [39] Verification of the association of the cycle threshold (Ct) values from HPV testing on Cobas4800 with the histologic grades of cervical lesions using data from two population-based cervical cancer screening trials
    Yi Zhang
    Hui Du
    Aimin Xiao
    Wei Zhang
    Chun Wang
    Xia Huang
    Xinfeng Qu
    Jianliu Wang
    Ruifang Wu
    Infectious Agents and Cancer, 17
  • [40] Human Papillomavirus Testing for Cervical Cancer Screening: Results From a 6-Year Prospective Study in Rural China
    Shi, Ju-Fang
    Belinson, Jerome L.
    Zhao, Fang-Hui
    Pretorius, Robert G.
    Li, Jing
    Ma, Jun-Fei
    Chen, Feng
    Xiang, Wang
    Pan, Qin-Jing
    Zhang, Xun
    Zhang, Wen-Hua
    Qiao, You-Lin
    Smith, Jennifer S.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 170 (06) : 708 - 716